EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury

Wenjie Lu, Yurong Tu, Renkai Wang, Minghao Jiang, Junyu Zhuang, Jiahui Song, Ping Wu, Sunren Sheng, Sipin Zhu, Zhouguang Wang

CNS Neuroscience & Therapeutics · 2026-08 · 32 (8)

DOI: 10.1002/cns.71086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.08.2026. Verfasst von Wenjie Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Medical University, …. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Toll-Like Receptor 4, NF-kappa B, Nerve Tissue Proteins. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Funding of China, Zhejiang Medical and Health Science and Technology Plan Project, National College Students Innovation and Entrepreneurship Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Spinal cord injury (SCI) can cause severe neurological dysfunction and the occurrence of chronic neuropathic pain, which can manifest as the occurrence of abnormal pain and hyperalgesia. Artemin (ARTN) is a member of the glial cell‐derived neurotrophic factor (GDNF) family ligand and can improve neural injury and regulate the occurrence of neuropathic pain. However, the process by which ARTN regulates inflammation and the sensitization of the dorsal horn of the spinal cord related to pain after SCI is still unclear.

Methods

ARTN‐Fc fusion protein was constructed and administered intrathecally to mice after SCI. Motor recovery and pain‐related behaviors were evaluated using behavioral, gait, electrophysiological, paw withdrawal latency, and formalin‐induced Fos assays. Molecular changes were assessed by Western blotting, immunofluorescence, and immunohistochemistry. In vitro, a BV2–PC12 Transwell co‐culture system was used to examine the effect of ARTN‐Fc on activated microglia‐mediated neuronal injury.

Results

ARTN‐Fc treatment significantly improved motor recovery and reduced thermal hyperalgesia after SCI. Mechanistically, ARTN‐Fc promoted microglial M2 polarization, inhibited TLR4/NF‐κB activation, suppressed pro‐inflammatory cytokine expression, and attenuated NLRP3 inflammasome/pyroptosis‐related signaling. In the spinal dorsal horn, ARTN‐Fc increased inhibitory GABAergic markers, including vGAT and GAD1, while reducing the excitatory marker vGluT2, suggesting altered inhibitory/excitatory synaptic marker expression. In vitro, ARTN‐Fc reduced neuronal apoptosis mediated by activated microglia.

Conclusion

Taken together, the results suggest that ARTN‐Fc is a potential therapeutic agent for SCI repair and neuropathic pain treatment by inhibiting the TLR4/NF‐κB pathway to suppress neuroinflammation and modulating inhibitory/excitatory synaptic marker expression in the spinal dorsal horn.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Cord InjuriesToll-Like Receptor 4NF-kappa BNerve Tissue ProteinsNeuroinflammatory DiseasesRecombinant Fusion ProteinsAnimalsMiceMaleMice, Inbred C57BLSynapsesHyperalgesiaRatsSignal Transduction

Stichwörter der Autor:innen

Artemin‐Fc fusion proteinTLR4/NF‐κBmicroglial polarizationneuropathic painspinal cord injury

Substanzen

Toll-Like Receptor 4NF-kappa BNerve Tissue ProteinsTlr4 protein, mouseRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
  • State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
  • The Second Clinical School of Wenzhou Medical University, Wenzhou, China.
  • Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.

Förderung

  • National Natural Science Funding of China
  • Zhejiang Medical and Health Science and Technology Plan Project
  • National College Students Innovation and Entrepreneurship Training Program
  • Wenzhou Major Science and Technology Innovation Project Approval Project

Zitieren

APA

Lu, W., Tu, Y., Wang, R., Jiang, M., Zhuang, J., Song, J., Wu, P., Sheng, S., Zhu, S., & Wang, Z. (2026). Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury. CNS Neuroscience & Therapeutics, 32(8). https://doi.org/10.1002/cns.71086

Vancouver

Lu W, Tu Y, Wang R, Jiang M, Zhuang J, Song J, et al. Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury. CNS Neuroscience & Therapeutics. 2026;32(8). doi:10.1002/cns.71086

BibTeX
@article{Lu2026,
  author = {Lu, Wenjie and Tu, Yurong and Wang, Renkai and Jiang, Minghao and Zhuang, Junyu and Song, Jiahui and Wu, Ping and Sheng, Sunren and Zhu, Sipin and Wang, Zhouguang},
  title = {Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {8},
  doi = {10.1002/cns.71086}
}
Kostenlos starten →